Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Herbie Newell

Newcastle AuthorsTitleYearFull text
Liz Matheson
Huw Thomas
Marian Case
Dr Helen Blair
Rosanna Jackson
et al.		Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM2019
Dr Catherine Drummond
Arman Esfandiari
Dr Xiaohong Lu
Dr Claire Hutton
Dr Jennifer Jackson
et al.		TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation2016
Dr Gary Beale
Dr Emma Haagensen
Huw Thomas
Lan Wang
Charlotte Revill
et al.		Combined PI3K and CDK2 inhibition induces cell death and enhances in vivo anti-tumour activity in colorectal cancer2016
Tristan Reuillon
Dr Sari Alhasan
Dr Gary Beale
Annalisa Bertoli
Alfie Brennan
et al.		Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases2016
Dr Emma Haagensen
Huw Thomas
Dr Ross Maxwell
Professor Herbie Newell
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-0372016
Dr Rachel Pearson
Professor Peter Thelwall
Jim Snell
Dr Piotr Pieniazek
Professor Rakesh Heer
et al.		Evaluation of early responses to neoadjuvant chemotherapy in muscle-invasive bladder cancer using a dynamic contrast-enhanced MRI and diffusion-weighted MRI: MARBLE study2016
Stephanie Myers
Dr Ruth Bawn
Betty Cottyn
Dr Lauren Molyneux
Dr Celine Cano
et al.		High-throughput screening and hit validation of extracellular-related kinase 5 (ERK5) inhibitors2016
Dr Emma Haagensen
Huw Thomas
Dr Ross Maxwell
Professor Herbie Newell
Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent2016
Dr Sari Alhasan
Dr Beate Haugk
Laura Ogle
Dr Gary Beale
Anna Long
et al.		Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma2016
Lan Wang
Professor Herbie Newell
Professor Steve Wedge
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation2016
1234567891011121314151617181920...